Although the EU Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746) are fully in force, the regulatory landscape remains highly dynamic. In recent years, the focus has shifted from transition to implementation, where harmonization has become increasingly important.
For manufacturers, this means that compliance is no longer defined solely by aligning with the core regulations. It requires continuous interpretation of evolving guidance, adapting to changes in expectations from Notified Bodies, and integrating new regulatory instruments such as common specifications and MDCG guidance into existing systems
Several regulatory updates over the past years have had a tangible operational impact:
1. MDCG Guidance Expansion and Interpretation Alignment
The steady release of MDCG guidance documents has significantly clarified - and in some cases redefined - expectations. For example:
Clinical strategies had to be revisited, templates updated, and teams retrained on how to apply these interpretations consistently.
2. EUDAMED Rollout and Actor Obligations
The phased rollout of EUDAMED modules introduced new operational requirements, particularly around:
Even without full system deployment, manufacturers have needed to prepare internal data structures, align labelling processes with UDI requirements, and establish governance around data accuracy and updates.
3. IVDR Transition Extensions (Regulation (EU) 2022/112 and 2023/607)
The extension of IVDR transition timelines significantly impacted planning strategies. While it provided relief, it also introduced:
This forced organizations to reassess product portfolios, certification timelines, and resource allocation. Ongoing uncertainty emerged through the IVDR 2.0 with potential simplification measures, regulatory harmonization efforts, and further adjustments to implementation expectations. Discover the implications of IVDR 2.0 in our on-demand webinar.
4. Increased Scrutiny from Notified Bodies
As Notified Bodies matured in their MDR/IVDR application, assessments became more consistent, and more rigorous. Common findings include:
This has required organizations to move beyond “documentation completion” toward true system integration and traceability across lifecycle processes.
A recurring challenge is not understanding what the regulation says, but how it is applied in practice. For example:
These are not isolated tasks; they require cross-functional alignment between regulatory, clinical, quality, and engineering teams. Given the pace and complexity of regulatory change, competence management has become a core element of compliance systems. This goes beyond awareness training and requires role-specific expertise (e.g., PRRC responsibilities under Article 15 MDR), up-to-date knowledge of guidance interpretation and the ability to assess regulatory impact on internal processes.
The direction is clear: increased regulatory scrutiny, further harmonization, and continued publication of guidance to close interpretation gaps. Topics such as artificial intelligence (AI), software qualification, and real-world evidence (RWE) are already gaining regulatory attention and will likely introduce additional layers of complexity.
For MedTech organizations, success under MDR and IVDR will depend less on one-time compliance efforts and more on the ability to continuously interpret, implement, and operationalize regulatory change across the organization.
In this environment, regulatory knowledge is no longer static, it is a continuously evolving capability that directly influences both compliance and market access.
Check out our Virtual Training Calender – Your yearly compliance plan to stay ahead of the curve.